Immune Function and the Progression to T1D

Purpose

To elucidate the mechanisms by which type 1 diabetes-associated genes; IFIH1, TYK2, IKZF4, as well as total genetic risk, impart functional immunoregulatory abnormalities that result in expansion of self-reactive adaptive immune cells, defective regulatory/effector mechanisms in T cells, inflammatory antigen presenting cells, and abnormal immune function in T cells and B cells.

Condition

  • Type 1 Diabetes

Eligibility

Eligible Ages
Between 0 Years and 100 Years
Eligible Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

able to have blood drawn -

Exclusion Criteria

none -

Study Design

Phase
Study Type
Observational
Observational Model
Other
Time Perspective
Cross-Sectional

Arm Groups

ArmDescriptionAssigned Intervention
Subjects with diabetes age 0 to 100 years People who have not been diagnosed with type 1 diabetes
  • Other: blood draw
    a peripheral blood draw
Subjects with type 1 diabetes age 0 to 100 years People who have been diagnosed with type 1 diabetes
  • Other: blood draw
    a peripheral blood draw

Recruiting Locations

Kieran McGrail
Gainesville, Florida 32610
Contact:
Kieran McGrail
352-273-9299
mcgrail@pathology.ufl.edu

The Ohio State University
Columbus, Ohio 43210
Contact:
Billur Akkaya, MD DPhil
614-688-1187
billur.akkaya@osumc.edu

Baylor College of Medicine, Center for Research Advancement - Texas Children's Hospital
Houston, Texas 77030
Contact:
Maria Redondo, MD, PhD, MPH
832-822-1019
redondo@bcm.edu

More Details

Status
Recruiting
Sponsor
University of Florida

Study Contact

Jennifer L Hosford, MPH
352-294-5759
jennifer.hosford@peds.ufl.edu

Detailed Description

Newly proposed studies will identify the inflammatory cues that draw immune cells into islets for disease initiation (Project 1); probe the motility of immune cells through inflamed vasculature to the target organ and antigen priming sites within secondary lymphatics (Project 2); and characterize the T1D-associated adaptive immune signatures in blood and immune tissues (Project 3). The overall hypothesis of the renewed P01 states: 1) the impact of T1D-risk variants will vary by tissue, cell subset, and activation state, and 2) risk variants, cellular stress, and defects in immunologic pathways are key to engender the autoimmune destruction of pancreatic B-cells that results in T1D.